

Liste des publications 2017 de l'ICO

Auteur(s)	Titre	Revue	Année	Vol.	Pages
Bailly, C ; Bodet-Milin, C ; Rousseau, C ; Faivre-Chauvet, A ; Kraeber-Bodéré, F ; Barbet, J	Pretargeting for imaging and therapy in oncological nuclear medicine.	EJNMMI Radiopharm Chem	2017	2	6
Faraj, S ; Bahri, M ; Fougeray, S ; El Roz, A ; Fleurence, J ; Véziers, J & al	Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside.	Oncoimmunology	2017	7	e1373232
O'Neil, BH ; Wallmark, JM ; Lorente, D ; Elez, E ; Raimbourg, J ; Gomez-Roca, C & al	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.	PLoS One	2017	12	e0189848
Tao, Y ; Auperin, A ; Sire, C ; Martin, M ; Saliou, MG ; Bardet, E & al	Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie Radiothérapie Tête et Cou) 2009-01 Evaluating the Effect of the Regenerating Agent on Radiodermatitis of Head and Neck Cancer Patients.	Int J Radiat Oncol Biol Phys	2017	99	590-595
Sjoquist, KM ; Renfro, LA ; Simes, RJ ; Tebbutt, NC ; Clarke, S ; Seymour, MT & al	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.	J Natl Cancer Inst	2017		
Rocheffort, P ; Italiano, A ; Laurence, V ; Penel, N ; Lardy-Cleaud, A ; Mir, O & al	A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome.	Sci Rep	2017	7	17917
Golmard, L ; Castéra, L ; Krieger, S ; Moncoutier, V ; Abidallah, K ; Tenreiro, H & al	Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.	Eur J Hum Genet	2017	25	1345-1353
Ternant, D ; Passot, C ; Aubourg, A ; Goupille, P ; Desvignes, C ; Picon, L & al	Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration.	Clin Pharmacokinet	2017		
Tranquart, F ; Dujardin, PA ; Bouché, O ; Marcus, C ; Borg, C ; Manzoni, P & al	Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver Metastases.	Ultraschall Med	2017		
Dal Pra, A ; Zilli, T ; Supiot, S	Editorial: Controversies and Perspectives in the Use of Postoperative Radiotherapy for Prostate Cancer.	Front Oncol	2017	7	275
Crenn, V ; Biteau, K ; Amiaud, J ; Dumars, C ; Guiho, R ; Vidal, L & al	Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling.	Am J Cancer Res	2017	7	2333-2349

Rio, E ; Purdam, C ; Girdwood, M ; Cook, J	Isometric Exercise to Reduce Pain in Patellar Tendinopathy In-Season; Is It Effective "on the Road?"	Clin J Sport Med	2017		
Duprez, C ; Vanlemmens, L ; Untas, A ; Antoine, P ; Lesur, A ; Loustalot, C & al	Emotional distress and subjective impact of the disease in young women with breast cancer and their spouses.	Future Oncol	2017	13	2667-2680
Nicolle, R ; Blum, Y ; Marisa, L ; Loncle, C ; Gayet, O ; Moutardier, V & al	Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts.	Cell Rep	2017	21	2458-2470
Houvenaeghel, G ; Quilichini, O ; Cohen, M ; Rey, F ; Classe, JM ; Mazouni, C & al	Sentinel lymph node biopsy validation for large tumors.	Int J Surg	2017	48	275-280
Robert, M ; Frenel, JS ; Bourbouloux, E ; Berton Rigaud, D ; Patsouris, A ; Augereau, P & al	Efficacy of buparlisib in treating breast cancer.	Expert Opin Pharmacother	2017	18	2007-2016
Brooks, N ; Campone, M ; Paddock, S ; Shortenhaus, S ; Grainger, D ; Zummo, J & al	Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII).	Drugs Context	2017	6	212507
Loriot, Y ; Pagliaro, L ; Fléchon, A ; Mardiak, J ; Geoffrois, L ; Kerbrat, P & al	Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.	Eur J Cancer	2017	87	140-146
Martin, M ; Holmes, FA ; Ejlertsen, B ; Delaloge, S ; Moy, B ; Iwata, H & al	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.	Lancet Oncol	2017	18	1688-1700
Wick, W ; Gorlia, T ; Bendszus, M ; Taphoorn, M ; Sahm, F ; Harting, I & al	Lomustine and Bevacizumab in Progressive Glioblastoma.	N Engl J Med	2017	377	1954-1963
Jobard, E ; Trédan, O ; Bachelot, T ; Vigneron, AM ; Ait-Oukhatar, CM ; Arnedos, M & al	Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients.	Oncotarget	2017	8	83570-83584
Heymann, MF ; Lézot, F ; Heymann, D	The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma.	Cell Immunol	2017		
Blay, JY ; Soibinet, P ; Penel, N ; Bompas, E ; Duffaud, F ; Stoeckle, E & al	Improved survival using specialized multidisciplinary board in sarcoma patients.	Ann Oncol	2017	28	2852-2859
Forissier, V ; Tallet, A ; Cohen, M ; Classe, JM ; Rey, F ; Chopin, N & al	Is post-mastectomy radiation therapy contributive in pN0-1mi breast cancer patients? Results of a French multi-centric cohort.	Eur J Cancer	2017	87	47-57
Vilgrain, V ; Pereira, H ; Assenat, E ; Guiu, B ; Ilonca, AD ; Pageaux, GP & al	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.	Lancet Oncol	2017	18	1624-1636

Jamet, B ; Carlier, T ; Campion, L ; Bompas, E ; Girault, S ; Borrely, F & al	Initial FDG-PET/CT predicts survival in adults Ewing sarcoma family of tumors.	Oncotarget	2017	8	77050-77060
Frenel, JS ; Le Tourneau, C ; O'Neil, B ; Ott, PA ; Piha-Paul, SA ; Gomez-Roca, C & al	Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.	J Clin Oncol	2017	35	4035-4041
Paris, C ; Do, P ; Mastroianni, B ; Dixmier, A ; Dumont, P ; Pichon, E & al	Association between lung cancer somatic mutations and occupational exposure in never-smokers.	Eur Respir J	2017	50	
Dafni, U ; Karlis, D ; Pedeli, X ; Bogaerts, J ; Pentheroudakis, G ; Tabernero, J & al	Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules.	ESMO Open	2017	2	e000216
Carné Trécesson, S ; Souazé, F ; Basseville, A ; Bernard, AC ; Pécot, J ; Lopez, J & al	directly modulates RAS signalling to favour cancer cell stemness.	Nat Commun	2017	8	1123
Mathot, P ; Grandin, M ; Devailly, G ; Souaze, F ; Cahais, V ; Moran, S & al	DNA methylation signal has a major role in the response of human breast cancer cells to the microenvironment.	Oncogenesis	2017	6	e390
Harford-Wright, E ; Andre-Gregoire, G ; Jacobs, KA ; Treps, L ; Le Gonidec, S ; Leclair, HM & al	Pharmacological targeting of apelin impairs glioblastoma growth.	Brain	2017	140	2939-2954
Vázquez-García, I ; Salinas, F ; Li, J ; Fischer, A ; Barré, B ; Hallin, J & al	Clonal Heterogeneity Influences the Fate of New Adaptive Mutations.	Cell Rep	2017	21	732-744
Legeay, C ; Bittencourt, H ; Haddad, E ; Spiesser-Robelet, L ; Thépot-Seegers, V ; Therrien, R	A Retrospective Study on Infusion-Related Reactions to Rituximab in a Heterogeneous Pediatric Population.	J Pediatr Pharmacol Ther	2017	22	369-374
Bagacean, C ; Tempescul, A ; Le Dantec, C ; Bordron, A ; Mohr, A ; Saad, H & al	Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemia.	Oncotarget	2017	8	65699-65716
Leblanc, D ; Conté, M ; Masson, G ; Richard, F ; Jeanneteau, A ; Bouhours, G & al	SmartPilot® view-guided anaesthesia improves postoperative outcomes in hip fracture surgery: a randomized blinded controlled study.	Br J Anaesth	2017	119	1022-1029
Saloustros, E ; Stark, DP ; Michailidou, K ; Mountzios, G ; Brugieres, L ; Peccatori, FA & al	The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey.	ESMO Open	2017	2	e000252
Bobin-Dubigeon, C ; Chauvin, A ; Brillaud-Meflah, V ; Boiffard, F ; Joalland, MP ; Bard, JM	Liver X Receptor (LXR)-regulated Genes of Cholesterol Trafficking and Breast Cancer Severity.	Anticancer Res	2017	37	5495-5498
Rat, C ; Hild, S ; Gaultier, A ; Khammari, A ; Bonnaud-Antignac, A ; Quereux, G & al	Anxiety, locus of control and sociodemographic factors associated with adherence to an annual clinical skin monitoring: a cross-sectional survey among 1000 high-risk French patients involved in a pilot-targeted screening programme for melanoma.	BMJ Open	2017	7	e016071
Robert, M ; Jarlier, M ; Gourgou, S ; Desseigne, F ; Ychou, M ; Bouché, O & al	Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a	Oncology	2017	93	367-376

	Randomized Phase III Study (ACCORD11/PRODIGE4).				
Keller, A ; Doré, M ; Cebula, H ; Thillays, F ; Proust, F ; Darié, I & al	Hypofractionated Stereotactic Radiation Therapy to the Resection Bed for Intracranial Metastases.	Int J Radiat Oncol Biol Phys	2017	99	1179-1189
Séry, Q ; Rabé, M ; Oliver, L ; Vallette, FM ; Gratas, C	HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide.	Biochem Biophys Res Commun	2017	493	1377-1383
Goetz, MP ; Toi, M ; Campone, M ; Sohn, J ; Paluch-Shimon, S ; Huober, J & al	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.	J Clin Oncol	2017	35	3638-3646
Guérard, F ; Navarro, L ; Lee, YS ; Roumesy, A ; Alliot, C ; Chérel, M & al	Bifunctional arylodonium salts for highly efficient radioiodination and astatination of antibodies.	Bioorg Med Chem	2017	25	5975-5980
Azria, D ; Doyen, J ; Jarlier, M ; Martel-Lafay, I ; Hennequin, C ; Etienne, P & al	Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer.	Ann Oncol	2017	28	2436-2442
Pitorre, M ; Gondé, H ; Haury, C ; Messous, M ; Poilane, J ; Boudaud, D & al	Recent advances in nanocarrier-loaded gels: Which drug delivery technologies against which diseases?	J Control Release	2017	266	140-155
Guerin, M ; Rezai, K ; Isambert, N ; Campone, M ; Autret, A ; Pakradouni, J & al	PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.	Eur J Cancer	2017	86	28-36
Cherny, NI ; Dafni, U ; Bogaerts, J ; Latino, NJ ; Pentheroudakis, G ; Douillard, JY & al	ESMO-Magnitude of Clinical Benefit Scale version 1.1.	Ann Oncol	2017	28	2340-2366
Moeung, S ; Chevreau, C ; Broutin, S ; Guitton, J ; Lelièvre, B ; Ciccolini, J & al	Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study.	Clin Cancer Res	2017	23	7171-7179
Birnbaum, DJ ; Finetti, P ; Lopresti, A ; Gilabert, M ; Poizat, F ; Raoul, JL & al	A 25-gene classifier predicts overall survival in resectable pancreatic cancer.	BMC Med	2017	15	170
Boutry, C ; Sors, A ; Fontaine, J ; Delaby, N ; Delpon, G	Technical Note: A simple algorithm to convert EPID gray values into absorbed dose to water without prior knowledge.	Med Phys	2017	44	6647-6653
Sarrut, D ; Halty, A ; Badel, JN ; Ferrer, L ; Bardiès, M	Voxel-based multimodel fitting method for modeling time activity curves in SPECT images.	Med Phys	2017	44	6280-6288
Saleh, Z ; Salleron, J ; Baffert, S ; Paveau, A ; Classe, JM ; Marchal, F	[Impact of the preservation of the branches of intercostobrachial nerve on the quality of life of patients operated for a breast cancer].	Bull Cancer	2017	104	858-868
Thierry, AR ; El Messaoudi, S ; Mollevi, C ; Raoul, JL ; Guimbaud, R ; Pezet, D & al	Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.	Ann Oncol	2017	28	2149-2159

Corre, I ; Paris, F ; Huot, J	The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells.	Oncotarget	2017	8	55684-55714
Raoul, JL ; Gilibert, M ; Adhouste, X ; Edeline, J	An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma.	Expert Opin Pharmacother	2017	18	1467-1476
Lisbona, A	[What does the medical physicist expect from the radiation oncologist and vice versa?]	Cancer Radiother	2017	21	560-562
Gnep, K ; Lizée, T ; Campillo-Gimenez, B ; Delpon, G ; Droupy, S ; Perrier, L & al	[Toxicity and quality of life comparison of iodine 125 brachytherapy and stereotactic radiotherapy for prostate cancers].	Cancer Radiother	2017	21	478-490
Gilibert, M ; Raoul, JL ; Rousseau, F	How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017?	J Geriatr Oncol	2017	8	407-412
Antonia, SJ ; Villegas, A ; Daniel, D ; Vicente, D ; Murakami, S ; Hui, R & al	Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.	N Engl J Med	2017	377	1919-1929
Hofland, J ; Ouattara, A ; Fellahi, JL ; Gruenewald, M ; Hazebroucq, J ; Ecoffey, C & al	Effect of Xenon Anesthesia Compared to Sevoflurane and Total Intravenous Anesthesia for Coronary Artery Bypass Graft Surgery on Postoperative Cardiac Troponin Release: An International, Multicenter, Phase 3, Single-blinded, Randomized Noninferiority Trial.	Anesthesiology	2017	127	918-933
Bibault, JE ; Dussart, S ; Pommier, P ; Morelle, M ; Huguet, M ; Boisselier, P & al	Clinical Outcomes of Several IMRT Techniques for Patients With Head and Neck Cancer: A Propensity Score-Weighted Analysis.	Int J Radiat Oncol Biol Phys	2017	99	929-937
Supiot, S ; Doré, M ; Rio, E	[Radiotherapy of oligometastatic pelvic node relapses in patients with prostate cancer].	Cancer Radiother	2017	21	495-497
Lacornerie, T ; Rio, E ; Mahé, MA	[Stereotactic body radiation therapy for hepatic malignancies: Organs at risk, uncertainties margins, doses].	Cancer Radiother	2017	21	574-579
Weller, M ; Butowski, N ; Tran, DD ; Recht, LD ; Lim, M ; Hirte, H & al	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.	Lancet Oncol	2017	18	1373-1385
Aapro, M ; Boccia, R ; Leonard, R ; Camps, C ; Campone, M ; Choquet, S & al	Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.	Support Care Cancer	2017	25	3295-3304
Kim, S ; Jary, M ; André, T ; Vendrely, V ; Buecher, B ; François, E & al	Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).	BMC Cancer	2017	17	574
Bailly, C ; Leforestier, R ; Campion, L ; Thebaud, E ;	Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant	PLoS One	2017	12	e0183841

Moreau, A ; Kraeber-Bodere, F & al	chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma.				
Salas, S ; Resseguier, N ; Blay, JY ; Le Cesne, A ; Italiano, A ; Chevreau, C & al	Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database.	Ann Oncol	2017	28	1979-1987
Miannay, B ; Minvielle, S ; Roux, O ; Drouin, P ; Avet-Loiseau, H ; Guérin-Charbonnel, C & al	Logic programming reveals alteration of key transcription factors in multiple myeloma.	Sci Rep	2017	7	9257
Curtit, E ; Pivot, X ; Henriques, J ; Paget-Bailly, S ; Fumoleau, P ; Rios, M & al	Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.	Breast Cancer Res	2017	19	98
Bascoul-Mollevis, C ; Gourgou, S ; Galais, MP ; Raoul, JL ; Bouché, O ; Douillard, JY & al	Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.	Eur J Cancer	2017	84	239-249
Bigot, F ; Castanon, E ; Baldini, C ; Hollebecque, A ; Carmona, A ; Postel-Vinay, S & al	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).	Eur J Cancer	2017	84	212-218
Ott, PA ; Elez, E ; Hirt, S ; Kim, DW ; Morosky, A ; Saraf, S & al	Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.	J Clin Oncol	2017	35	3823-3829
Delaunay, M ; Cadranel, J ; Lusque, A ; Meyer, N ; Gounant, V ; Moro-Sibilot, D & al	Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.	Eur Respir J	2017	50	
de Nonneville, A ; Gonçalves, A ; Zemmour, C ; Cohen, M ; Classe, JM ; Reyat, F & al	Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.	Eur J Cancer	2017	84	34-43
Basse, C ; Thureau, S ; Bota, S ; Dansin, E ; Thomas, PA ; Pichon, E & al	Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort.	J Thorac Oncol	2017	12	1715-1722
Passot, C ; Desvignes, C ; Ternant, D ; Bejan-Angoulvant, T ; Duveau, AC ; Gatault, P & al	Development and validation of an enzyme-linked immunosorbent assay to measure free eculizumab concentration in serum.	Bioanalysis	2017	9	1227-1235
Douillard, JY	ESMO Copenhagen 2016: a lung cancer "grand cru".	ESMO Open	2017	2	e000196
Chouaid, C ; Luciani, L ; LeLay, K ; Do, P ; Bennouna, J ; Perol, M & al	Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers.	J Thorac Oncol	2017	12	1496-1502

Carbonnelle, D ; Luu, TH ; Chaillou, C ; Huvelin, JM ; Bard, JM ; Nazih, H	LXR Activation Down-regulates Lipid Raft Markers FLOT2 and DHHC5 in MCF-7 Breast Cancer Cells.	Anticancer Res	2017	37	4067-4073
Penel, N ; Le Cesne, A ; Bonvalot, S ; Giraud, A ; Bompas, E ; Rios, M & al	Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group.	Eur J Cancer	2017	83	125-131
Demoor-Goldschmidt, C ; Supiot, S ; Oberlin, O ; Helfre, S ; Vigneron, C ; Brillaud-Meflah, V & al	Clinical and diagnosis characteristics of breast cancers in women with a history of radiotherapy in the first 30years of life: A French multicentre cohort study.	Radiother Oncol	2017	124	200-203
Marcy, PY ; Schiappa, R ; Ferrero, JM ; Dahlet, C ; Brenet, O ; Yazbec, G & al	Patient satisfaction and acceptance of their totally implanted central venous catheter: a French prospective multicenter study.	J Vasc Access	2017	18	390-395
Oizel, K ; Chauvin, C ; Oliver, L ; Gratas, C ; Geraldo, F ; Jarry, U & al	Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity.	Clin Cancer Res	2017	23	6292-6304
Robert, J ; Sorrieul, J ; Rossignol, E ; Beaussart, H ; Kieffer, H ; Folliard, C & al	Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia.	Int J Pharm Compd	2017	21	347-351
Passot, C ; Pouw, MF ; Mulleman, D ; Bejan-Angoulvant, T ; Paintaud, G ; Dreesen, E & al	Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling.	Ther Drug Monit	2017	39	322-326
Gottfried, M ; Bennouna, J ; Bondarenko, I ; Douillard, JY ; Heigener, DF ; Krzakowski, M & al	Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.	Target Oncol	2017	12	475-485
Dubois, C ; Morin, F ; Moro-Sibilot, D ; Langlais, A ; Seitz, JF ; Girault, C & al	[Clinical research activity of the French cancer cooperative network: Overview and perspectives].	Bull Cancer	2017	104	652-661
Raoul, JL ; Maraninchi, D	[Patient participation in medical decision-making: From concept to reality in oncology].	Bull Cancer	2017	104	695-700
Tao, Y ; Aupérin, A ; Graff, P ; Lapeyre, M ; Grégoire, V ; Maingon, P & al	Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.	Oral Oncol	2017	71	61-66
Moreau, P ; Attal, M ; Caillot, D ; Macro, M ; Karlin, L ; Garderet, L & al	F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.	J Clin Oncol	2017	35	2911-2918
Rugo, HS ; Trédan, O ; Ro, J ; Morales, SM ; Campone, M ; Musolino, A & al	A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.	Breast Cancer Res Treat	2017	165	601-609

Harousseau, JL ; Attal, M	How I treat first relapse of myeloma.	Blood	2017	130	963-973
Bennouna, J	Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer.	Future Oncol	2017	13	1829-1833
Emile, JF ; Julié, C ; Le Malicot, K ; Lepage, C ; Tabernero, J ; Mini, E & al	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.	Eur J Cancer	2017	82	16-24
Pivot, X ; Romieu, G ; Fumoleau, P ; Rios, M ; Bonnefoi, H ; Bachelot, T & al	Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort.	NPJ Breast Cancer	2017	3	4
Dupoiron, D ; Stachowiak, A ; Loewenstein, O ; Ellery, A ; Kremers, W ; Bosse, B & al	A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.	Eur J Pain	2017	21	1528-1537
Gligorov, J ; Ataseven, B ; Verrill, M ; De Laurentiis, M ; Jung, KH ; Azim, HA & al	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.	Eur J Cancer	2017	82	237-246
Classe, JM ; Guyon, F ; Falandry, C ; Devouassoux-Shisheboran, M ; Selle, F ; Joly, F		Bull Cancer	2017	104 Suppl 1	S6-S15
Floquet, A ; Berton-Rigaud, D ; Ferron, G ; Freyer, G ; Hardy-Bessard, AC ; You, B		Bull Cancer	2017	104 Suppl 1	S24-S31
Pivot, X ; Fumoleau, P ; Pierga, JY ; Delaloge, S ; Bonnefoi, H ; Bachelot, T & al	Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.	Eur J Cancer	2017	81	151-160
Damaj, GL ; Benbrahim, O ; Hacini, M ; Voronina, I ; Benabed, K ; Soumoudronga, RF & al	ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies.	Clin Lymphoma Myeloma Leuk	2017	17	362-369.e2
Latorzeff, I ; Sargos, P ; Loos, G ; Supiot, S ; Guerif, S ; Carrie, C	Delineation of the Prostate Bed: The "Invisible Target" Is Still an Issue?	Front Oncol	2017	7	108
Valmary-Degano, S ; Colpart, P ; Villeneuve, L ; Monnien, F ; M""Hamdi, L ; Lang Averous, G & al	Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.	Eur J Surg Oncol	2017	43	1915-1923
Olivier, PY ; Beloncle, F ; Seegers, V ; Tabka, M ; Renou de La Bourdonnaye, M ; Mercat, A & al) in a rat model with severe sepsis.	Ann Intensive Care	2017	7	66

Gilabert, M ; Boher, JM ; Raoul, JL ; Paye, F ; Bachellier, P ; Turrini, O & al	Comparison of preoperative imaging and pathological findings for pancreatic head adenocarcinoma: A retrospective analysis by the Association Française de Chirurgie.	Medicine (Baltimore)	2017	96	e7214
Raoul, JL ; Gilabert, M	Hepatocellular Carcinoma: Slow Progress in a Booming Epidemic.	J Oncol Pract	2017	13	365-366
de Las Heras Gala, H ; Torresin, A ; Dasu, A ; Rampado, O ; Delis, H ; Hernández Girón, I & al	Quality control in cone-beam computed tomography (CBCT) EFOMP-ESTRO-IAEA protocol (summary report).	Phys Med	2017	39	67-72
Aboagye, EO ; Kraeber-Bodéré, F	Highlights lecture EANM 2016: "Embracing molecular imaging and multi-modal imaging: a smart move for nuclear medicine towards personalized medicine".	Eur J Nucl Med Mol Imaging	2017	44	1559-1574
Adhoue, X ; Péñaranda, G ; Raoul, JL ; Bourlière, M	Usefulness of the MESH score in a European hepatocellular carcinoma cohort.	World J Hepatol	2017	9	711-714
Roncolato, FT ; Joly, F ; O'Connell, R ; Lanceley, A ; Hilpert, F ; Buizen, L & al	Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer- The GClG Symptom Benefit Study.	Oncologist	2017	22	1117-1124
Jouenne, F ; Chauvot de Beauchene, I ; Bollaert, E ; Avril, MF ; Caron, O ; Ingster, O & al	/P16INK4A mutations contribute to genetic determinism of sarcoma.	J Med Genet	2017	54	607-612
Peters, S ; Camidge, DR ; Shaw, AT ; Gadgeel, S ; Ahn, JS ; Kim, DW & al	Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.	N Engl J Med	2017	377	829-838
Arnoult, C ; Brachet, G ; Cadena Castaneda, D ; Azzopardi, N ; Passot, C ; Desvignes, C & al	Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti-TNF- α Antibodies after a Single Injection in Mice.	J Immunol	2017	199	418-424
Dufreneix, S ; Legrand, C ; Di Bartolo, C ; Bremaud, M ; Mesgouez, J ; Tiplica, T & al	Design of experiments in medical physics: Application to the AAA beam model validation.	Phys Med	2017	41	26-32
von Minckwitz, G ; Procter, M ; de Azambuja, E ; Zardavas, D ; Benyunes, M ; Viale, G & al	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.	N Engl J Med	2017	377	122-131
Baselga, J ; Im, SA ; Iwata, H ; Cortés, J ; De Laurentiis, M ; Jiang, Z & al	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.	Lancet Oncol	2017	18	904-916
Alligand, B ; Le Breton, M ; Marquis, D ; Vallette, F ; Fleury, F	Functional effects of diphosphomimetic mutations at cAbl-mediated phosphorylation sites on Rad51 recombinase activity.	Biochimie	2017	139	115-124
Andriantsoa, M ; Hoibian, S ; Autret, A ; Gilabert, M ; Sarran, A ; Niccoli, P & al	An elevated serum alkaline phosphatase level in hepatic metastases of grade 1 and 2 gastrointestinal neuroendocrine tumors is unusual and of prognostic value.	PLoS One	2017	12	e0177971

Keller, A ; Doré, M ; Antoni, D ; Menoux, I ; Thillays, F ; Clavier, JB & al	[Risk of radionecrosis after hypofractionated stereotactic radiotherapy targeting the postoperative resection cavity of brain metastases].	Cancer Radiother	2017	21	377-388
Bataille, P ; Reynard, A ; Ducarme, G	Spontaneous heterotopic triplets - A review of literature.	J Gynecol Obstet Hum Reprod	2017	46	657-659
Colomba, E ; Le Teuff, G ; Eisen, T ; Stewart, GD ; Fife, K ; Larkin, J & al	Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.	Eur J Cancer	2017	80	55-62
Paul-Gilloteaux, P ; Potiron, V ; Delpon, G ; Supiot, S ; Chiavassa, S ; Paris, F & al	Optimizing radiotherapy protocols using computer automata to model tumour cell death as a function of oxygen diffusion processes.	Sci Rep	2017	7	2280
Augereau, P ; Patsouris, A ; Bourbouloux, E ; Gourmelon, C ; Abadie Lacourtoisie, S ; Berton Rigaud, D & al	Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.	Ther Adv Med Oncol	2017	9	335-346
Boydev, C ; Demol, B ; Pasquier, D ; Saint-Jalmes, H ; Delpon, G ; Reynaert, N	Zero echo time MRI-only treatment planning for radiation therapy of brain tumors after resection.	Phys Med	2017	42	332-338
Harousseau, JL ; Avet-Loiseau, H	Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy.	J Clin Oncol	2017	35	2863-2865
Raimbourg, J ; Joalland, MP ; Cabart, M ; de Plater, L ; Bouquet, F ; Savina, A & al	Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib.	Mol Cancer Ther	2017	16	1634-1644
Robert, A ; Pointreau, Y ; Janoray, G ; Bardet, É ; Fesneau, M ; Garaud, P & al	A large French multicenter retrospective series of T1-T2N0 vocal cords carcinomas treated with exclusive irradiation.	Cancer Radiother	2017	21	286-290
Kerbrat, P ; Desmoulins, I ; Roca, L ; Levy, C ; Lortholary, A ; Marre, A & al	Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).	Eur J Cancer	2017	79	166-175
Pougnat, I ; Jaegle, E ; Garcia, R ; Tessier, F ; Faivre, JC ; Louvel, G & al	[Spinal stereotactic body radiotherapy: French assessment in 2016].	Cancer Radiother	2017	21	276-285
Demoor-Goldschmidt, C ; Drui, D ; Doutriaux, I ; Michel, G ; Auquier, P ; Dumas, A & al	A French national breast and thyroid cancer screening programme for survivors of childhood, adolescent and young adult (CAYA) cancers - DeNaCaPST programme.	BMC Cancer	2017	17	326
Bétrian, S ; Bergeron, C ; Blay, JY ; Bompas, E ; Cassier, PA ; Chevallier, L & al	Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC"s).	Clin Sarcoma Res	2017	7	10
Ott, PA ; Bang, YJ ; Berton-Rigaud, D ; Elez, E ; Pishvaian, MJ ; Rugo, HS & al	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.	J Clin Oncol	2017	35	2535-2541

Paintaud, G ; Passot, C ; Ternant, D ; Bertolotto, A ; Bejan-Angoulvant, T ; Pascual-Salcedo, D & al	Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases.	Ther Drug Monit	2017	39	339-343
Etienne-Grimaldi, MC ; Boyer, JC ; Beroud, C ; Mbatchi, L ; van Kuilenburg, A ; Bobin-Dubigeon, C & al	New advances in DPYD genotype and risk of severe toxicity under capecitabine.	PLoS One	2017	12	e0175998
Lebellec, L ; Chauffert, B ; Blay, JY ; Le Cesne, A ; Chevreau, C ; Bompas, E & al	Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).	Eur J Cancer	2017	79	119-128
Davies, A ; Merli, F ; Mihaljević, B ; Mercadal, S ; Siritanaratkul, N ; Solal-Céligny, P & al	Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.	Lancet Haematol	2017	4	e272-e282
Houvenaeghel, G ; Lambaudie, E ; Cohen, M ; Classe, JM ; Reyat, F ; Garbay, JR & al	Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB).	Breast	2017	34	24-33
Dupoiron, D ; Stachowiak, A ; Loewenstein, O ; Ellery, A ; Kremers, W ; Bosse, B & al	Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.	Eur J Pain	2017	21	1485-1494
Bourgeois, H ; Grudé, F ; Solal-Céligny, P ; Dupuis, O ; Voog, E ; Ganem, G & al	Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study.	Ann Oncol	2017	28	1612-1617
Ghouadni, A ; Delalogue, S ; Lardelli, P ; Kahatt, C ; Byrski, T ; Blum, JL & al	Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.	Breast	2017	34	18-23
Adhoute, X ; Pénaranda, G ; Raoul, JL ; Edeline, J ; Blanc, JF ; Pol, B & al	Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.	World J Gastroenterol	2017	23	2545-2555
Dezellus, A ; Barriere, P ; Campone, M ; Lemanski, C ; Vanlemmens, L ; Mignot, L & al	Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.	Eur J Cancer	2017	79	72-80
Pernot, S ; Badoual, C ; Terme, M ; Castan, F ; Cazes, A ; Bouche, O & al	Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.	Eur J Cancer	2017	79	15-22

Bleiberg, H ; Decoster, G ; de Gramont, A ; Rougier, P ; Sobrero, A ; Benson, A & al	A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group.	Ann Oncol	2017	28	922-930
Ott, PA ; Piha-Paul, SA ; Munster, P ; Pishvaian, MJ ; van Brummelen, EMJ ; Cohen, RB & al	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.	Ann Oncol	2017	28	1036-1041
Shepherd, FA ; Lacas, B ; Le Teuff, G ; Hainaut, P ; Jänne, PA ; Pignon, JP & al	Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.	J Clin Oncol	2017	35	2018-2027
Boeckx, N ; Koukakis, R ; Op de Beeck, K ; Rolfo, C ; Van Camp, G ; Siena, S & al	Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.	Ann Oncol	2017	28	1862-1868
Bourgeois, M ; Bailly, C ; Frindel, M ; Guerard, F ; Chérel, M ; Faivre-Chauvet, A & al	Radioimmunoconjugates for treating cancer: recent advances and current opportunities.	Expert Opin Biol Ther	2017	17	813-819
Lim, A ; Le Sourd, S ; Senellart, H ; Luet, D ; Douane, F ; Perret, C & al	Hepatic Arterial Infusion Chemotherapy for Unresectable Liver Metastases of Colorectal Cancer: A Multicenter Retrospective Study.	Clin Colorectal Cancer	2017	16	308-315
Duffaud, F ; Meeus, P ; Bertucci, F ; Delhorme, JB ; Stoeckle, E ; Isambert, N & al	Patterns of care and clinical outcomes in primary oesophageal gastrointestinal stromal tumours (GIST): A retrospective study of the French Sarcoma Group (FSG).	Eur J Surg Oncol	2017	43	1110-1116
Lafargue, A ; Degorre, C ; Corre, I ; Alves-Guerra, MC ; Gaugler, MH ; Vallette, F & al	Ionizing radiation induces long-term senescence in endothelial cells through mitochondrial respiratory complex II dysfunction and superoxide generation.	Free Radic Biol Med	2017	108	750-759
Bonnetain, F ; Borg, C ; Adams, RR ; Ajani, JA ; Benson, A ; Bleiberg, H & al	How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.	Ann Oncol	2017	28	2077-2085
Denis, F ; Lethrosne, C ; Pourel, N ; Molinier, O ; Pointreau, Y ; Domont, J & al	Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients.	J Natl Cancer Inst	2017	109	
Gilbert, M ; Chanez, B ; Rho, YS ; Giovanini, M ; Turrini, O ; Batist, G & al	Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.	Medicine (Baltimore)	2017	96	e6544
Renfro, LA ; Goldberg, RM ; Grothey, A ; Sobrero, A ; Adams, R ; Seymour, MT & al	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.	J Clin Oncol	2017	35	1929-1937
Arnold, D ; Lueza, B ; Douillard, JY ; Peeters, M ; Lenz, HJ ; Venook, A & al	Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.	Ann Oncol	2017	28	1713-1729

Dauplat, J ; Kwiatkowski, F ; Rouanet, P ; Delay, E ; Clough, K ; Verhaeghe, JL & al	Quality of life after mastectomy with or without immediate breast reconstruction.	Br J Surg	2017	104	1197-1206
Bachet, JB ; Hammel, P ; Desramé, J ; Meurisse, A ; Chibaudel, B ; André, T & al	Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.	Lancet Gastroenterol Hepatol	2017	2	337-346
Jourjon, R ; Morel, B ; Irtan, S ; Audureau, E ; Coulomb-L'Herminé, A ; Larroquet, M & al	Analysis of Clinical and Ultrasound Determinants of Adnexal Torsion in Children and Adolescents.	J Pediatr Adolesc Gynecol	2017	30	582-590
Boisdron-Celle, M ; Metges, JP ; Capitain, O ; Adenis, A ; Raoul, JL ; Lecomte, T & al	A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification.	Semin Oncol	2017	44	24-33
Boisdron-Celle, M ; Capitain, O ; Faroux, R ; Borg, C ; Metges, JP ; Galais, MP & al	Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.	Semin Oncol	2017	44	13-23
Robert, M ; Frenel, JS ; Gourmelon, C ; Patsouris, A ; Augereau, P ; Campone, M	Olaparib for the treatment of breast cancer.	Expert Opin Investig Drugs	2017	26	751-759
Attal, M ; Lauwers-Cances, V ; Hulin, C ; Leleu, X ; Caillot, D ; Escoffre, M & al	Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.	N Engl J Med	2017	376	1311-1320
Demoor-Goldschmidt, C ; Chiavassa, S ; Josset, S ; Mahé, MA ; Supiot, S	Respiratory-gated bilateral pulmonary radiotherapy for Ewing's sarcoma and neuroblastoma in children and young adults: Dosimetric and clinical feasibility studies.	Cancer Radiother	2017	21	124-129
Poveda, A ; Del Campo, JM ; Ray-Coquard, I ; Alexandre, J ; Provansal, M ; Guerra Alía, EM & al	Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.	Ann Oncol	2017	28	1280-1287
Poli, C ; Augusto, JF ; Dauvé, J ; Adam, C ; Preisser, L ; Larochette, V & al	IL-26 Confers Proinflammatory Properties to Extracellular DNA.	J Immunol	2017	198	3650-3661
Chanez, B ; Bertucci, F ; Gilibert, M ; Madroszyk, A ; Rousseau, F ; Perrot, D & al	A scoring system to guide the decision for a new systemic treatment after at least two lines of palliative chemotherapy for metastatic cancers: a prospective study.	Support Care Cancer	2017	25	2715-2722
Clement-Colmou, K ; Roualdes, V ; Martin, SA ; Josset, S ; Desal, H ; Campion, L & al	Dynamic conformal arc radiosurgery for arteriovenous malformations: Outcome and influence of clinical and dosimetric data.	Radiother Oncol	2017	123	251-256
Phelan, CM ; Kuchenbaecker, KB ; Tyrer, JP ; Kar, SP ; Lawrenson, K ; Winham, SJ & al	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.	Nat Genet	2017	49	680-691
Guérard, F ; Beyler, M ; Lee, YS ; Tripiet, R ; Gustin, JF ; Brechbiel, MW	Zr(IV) by hydroxypyridinones for the development of chelators for PET imaging applications.	Dalton Trans	2017	46	4749-4758

Vilote, F ; Antoine, M ; Bobin, M ; Latorzeff, I ; Supiot, S ; Richaud, P & al	Post-Prostatectomy Image-Guided Radiotherapy: The Invisible Target Concept.	Front Oncol	2017	7	34
Girot, P ; Dumars, C ; Mosnier, JF ; Muzellec, L ; Senellart, H ; Foubert, F & al	Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.	Eur J Gastroenterol Hepatol	2017	29	826-830
Besse, B ; Mazières, J ; Ribassin-Majed, L ; Barlesi, F ; Bennouna, J ; Gervais, R & al	Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.	Ann Oncol	2017	28	1078-1083
Catton, CN ; Lukka, H ; Gu, CS ; Martin, JM ; Supiot, S ; Chung, PWM & al	Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.	J Clin Oncol	2017	35	1884-1890
Bertucci, F ; Birnbaum, DJ ; Finetti, P ; Gilibert, M ; Poizat, F ; Raoul, JL & al	Prognostic Value of Molecular Subtypes in Pancreatic Cancer.	Pancreas	2017	46	e29-e31
Brown, HK ; Schiavone, K ; Tazzyman, S ; Heymann, D ; Chico, TJ	Zebrafish xenograft models of cancer and metastasis for drug discovery.	Expert Opin Drug Discov	2017	12	379-389
Bennouna, J ; Phelip, JM ; André, T ; Asselain, B ; Sébastien Koné, ; Ducreux, M	Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).	Clin Colorectal Cancer	2017	16	129-140.e4
Bian, B ; Bigonnet, M ; Gayet, O ; Loncle, C ; Maignan, A ; Gilibert, M & al	Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts.	EMBO Mol Med	2017	9	482-497
Nanni, C ; Cottreau, AS ; Lopci, E ; Bodet-Milin, C ; Coronado, M ; Pro, B & al	Report of the 6th International Workshop on PET in lymphoma.	Leuk Lymphoma	2017	58	2298-2303
Benslimane-Ahmim, Z ; Pereira, J ; Lokajczyk, A ; Dizier, B ; Galy-Fauroux, I ; Fischer, AM & al	Osteoprotegerin regulates cancer cell migration through SDF-1/CXCR4 axis and promotes tumour development by increasing neovascularization.	Cancer Lett	2017	395	11-19
Vera, P ; Thureau, S ; Chaumet-Riffaud, P ; Modzelewski, R ; Bohn, P ; Vermandel, M & al	F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study).	J Nucl Med	2017	58	1045-1053
Bigot, F ; Bonnet, C ; Massard, C	[Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].	Bull Cancer	2017	104	370-379
Lioger, B ; Edupuganti, SR ; Mulleman, D ; Passot, C ; Desvignes, C ; Bejan-Angoulvant, T & al	Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients.	Br J Clin Pharmacol	2017	83	1773-1781
Asfar, P ; Schortgen, F ; Boisramé-Helms, J ; Charpentier, J ; Guérot, E ; Megarbane, B & al	Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial.	Lancet Respir Med	2017	5	180-190

Bailly, C ; Leforestier, R ; Jamet, B ; Carlier, T ; Bourgeois, M ; Guérard, F & al	PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients.	Int J Mol Sci	2017	18	
Aubin, GG ; Baud""huin, M ; Lavigne, JP ; Brion, R ; Gouin, F ; Lepelletier, D & al	Interaction of Cutibacterium (formerly Propionibacterium) acnes with bone cells: a step toward understanding bone and joint infection development.	Sci Rep	2017	7	42918
Villeneuve, L ; Passot, G ; Glehen, O ; Isaac, S ; Bibeau, F ; Rousset, P & al	The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry.	Orphanet J Rare Dis	2017	12	37
Moserova, I ; Truxova, I ; Garg, AD ; Tomala, J ; Agostinis, P ; Cartron, PF & al	Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death.	Oncoimmunology	2017	6	e1258505
Adhoue, X ; Pénaranda, G ; Raoul, JL ; Bollon, E ; Pol, B ; Letreut, YP & al	NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.	Eur J Gastroenterol Hepatol	2017	29	706-715
Joly, F ; Eymard, JC ; Albiges, L ; Nguyen, T ; Guillot, A ; Rolland, F & al	A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France.	Support Care Cancer	2017	25	2055-2062
Tellez-Gabriel, M ; Charrier, C ; Brounais-Le Royer, B ; Mullard, M ; Brown, HK ; Verrecchia, F & al	Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip.	Eur J Cell Biol	2017	96	110-118
Musolino, A ; Campone, M ; Neven, P ; Denduluri, N ; Barrios, CH ; Cortes, J & al	breast cancer that had progressed during or after prior endocrine therapy.	Breast Cancer Res	2017	19	18
Peyraga, G ; Lizee, T ; Gustin, P ; Clement-Colmou, K ; Di Bartolo, C ; Supiot, S & al	Treatment of cutaneous and/or soft tissue manifestations of corticosteroids refractory chronic graft versus host disease (cGVHD) by a total nodal irradiation (TNI).	Clin Transplant	2017	31	
Niaudet, C ; Bonnaud, S ; Guillonau, M ; Gouard, S ; Gaugler, MH ; Dutoit, S & al	Plasma membrane reorganization links acid sphingomyelinase/ceramide to p38 MAPK pathways in endothelial cells apoptosis.	Cell Signal	2017	33	10-21
Pierga, JY ; Bidard, FC ; Autret, A ; Petit, T ; Andre, F ; Dalenc, F & al	Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.	Ann Oncol	2017	28	103-109
Higgins, M ; Curigliano, G ; Dieras, V ; Kuemmel, S ; Kunz, G ; Fasching, PA & al	Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.	Breast Cancer Res Treat	2017	162	479-488
Fumeron, F ; Bard, JM ; Lecerf, JM	Interindividual variability in the cholesterol-lowering effect of	Nutr Rev	2017	75	134-145

	supplementation with plant sterols or stanols.				
de Nonneville, A ; Gonçalves, A ; Zemmour, C ; Classe, JM ; Cohen, M ; Lambaudie, E & al	Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.	Breast Cancer Res Treat	2017	162	307-316
Fleurence, J ; Fougeray, S ; Bahri, M ; Cochonneau, D ; Clémenceau, B ; Paris, F & al	-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.	J Immunol Res	2017	2017	5604891
Bobin, M ; Zacharatou, C ; Sargos, P ; Brouste, V ; Lisbona, A ; Mahé, MA & al	Helical tomotherapy of spinal chordomas: French Multicentric, retrospective study of a cohort of 30 cases.	Radiat Oncol	2017	12	32
Lencioni, R ; Montal, R ; Torres, F ; Park, JW ; Decaens, T ; Raoul, JL & al	Objective response by mRECIST as a predictor and potential surrogate endpoint of overall survival in advanced HCC.	J Hepatol	2017	66	1166-1172
Pigneux, A ; Béné, MC ; Guardiola, P ; Recher, C ; Hamel, JF ; Sauvezie, M & al	Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study.	J Clin Oncol	2017	35	387-393
Faure, M ; Niccoli, P ; Autret, A ; Cavaglione, G ; Mineur, L ; Raoul, JL	Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer.	Mol Clin Oncol	2017	6	44-48
Gueguinou, M ; Crottès, D ; Chantôme, A ; Rapetti-Mauss, R ; Potier-Cartereau, M ; Clarysse, L & al		Oncogene	2017	36	3640-3647
Luu, TH ; Michel, C ; Bard, JM ; Dravet, F ; Nazih, H ; Bobin-Dubigeon, C	Intestinal Proportion of Blautia sp. is Associated with Clinical Stage and Histoprognostic Grade in Patients with Early-Stage Breast Cancer.	Nutr Cancer	2017	69	267-275
Tensaouti, F ; Ducassou, A ; Chaltiel, L ; Bolle, S ; Muracciole, X ; Coche-Dequeant, B & al	Patterns of failure after radiotherapy for pediatric patients with intracranial ependymoma.	Radiother Oncol	2017	122	362-367
Heudel, PE ; Fabbro, M ; Roemer-Becuwe, C ; Kaminsky, MC ; Arnaud, A ; Joly, F & al	Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.	Br J Cancer	2017	116	303-309
Bobin-Dubigeon, C ; Lefrançois, A ; Vansteene, D ; Dupé, M ; Joalland, MP ; Bard, JM	Leptin and adiponectin as new markers of undernutrition in cancer.	Clin Biochem	2017	50	525-528
Palpacuer, C ; Gallet, L ; Drapier, D ; Reymann, JM ; Falissard, B ; Naudet, F	Specific and non-specific effects of psychotherapeutic interventions for depression: Results from a meta-analysis of 84 studies.	J Psychiatr Res	2017	87	95-104
Vychnevskaiia, K ; Dumont, F ; Agostini, J ; Julié, C ; Dartigues, P ; Lazure, T & al	Prognostic Value of Sterilized Lymph Nodes After Preoperative Chemoradiotherapy for Patients with ypN0 Rectal Cancer.	Ann Surg Oncol	2017	24	1304-1311
Luque Paz, D ; Chauveau, A ; Boyer, F ; Buors, C ; Samaison, L ; Cottin, L & al	Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an	Genes Chromosomes Cancer	2017	56	354-362

	association between mutational status and clinical outcome.				
Delacour-Billon, S ; Mathieu-Wacquant, AL ; Campone, M ; Auffret, N ; Amossé, S ; Allieux, C & al	Short-term and long-term survival of interval breast cancers taking into account prognostic features.	Cancer Causes Control	2017	28	69-76
Rochigneux, P ; Raoul, JL ; Beaussant, Y ; Aubry, R ; Goldwasser, F ; Tournigand, C & al	Use of chemotherapy near the end of life: what factors matter?	Ann Oncol	2017	28	809-817
Belin, L ; Kamal, M ; Mauborgne, C ; Plancher, C ; Mulo, F ; Delord, JP & al	Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.	Ann Oncol	2017	28	590-596
Kraeber-Bodere, F ; Pallardy, A ; Maisonneuve, H ; Campion, L ; Moreau, A ; Soubeyran, I & al	Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.	Lancet Haematol	2017	4	e35-e45
Doré, M ; Martin, S ; Delpon, G ; Clément, K ; Campion, L ; Thillays, F	Stereotactic radiotherapy following surgery for brain metastasis: Predictive factors for local control and radionecrosis.	Cancer Radiother	2017	21	4-9
Brown, HK ; Tellez-Gabriel, M ; Heymann, D	Cancer stem cells in osteosarcoma.	Cancer Lett	2017	386	189-195
Gandara, DR ; Leighl, N ; Delord, JP ; Barlesi, F ; Bennouna, J ; Zalcman, G & al	A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.	J Thorac Oncol	2017	12	556-566
Nogova, L ; Sequist, LV ; Perez Garcia, JM ; Andre, F ; Delord, JP ; Hidalgo, M & al	Evaluation of BGI398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.	J Clin Oncol	2017	35	157-165
Ducreux, M ; Bennouna, J ; Adenis, A ; Conroy, T ; Lièvre, A ; Portales, F & al	Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial.	Cancer Chemother Pharmacol	2017	79	9-16
Chemel, M ; Brion, R ; Segaliny, AI ; Lamora, A ; Charrier, C ; Brulin, B & al	Bone Morphogenetic Protein 2 and Transforming Growth Factor β 1 Inhibit the Expression of the Proinflammatory Cytokine IL-34 in Rheumatoid Arthritis Synovial Fibroblasts.	Am J Pathol	2017	187	156-162
Hochane, M ; Trichet, V ; Pecqueur, C ; Avril, P ; Oliver, L ; Denis, J & al	Low-Dose Pesticide Mixture Induces Senescence in Normal Mesenchymal Stem Cells (MSC) and Promotes Tumorigenic Phenotype in Premalignant MSC.	Stem Cells	2017	35	800-811
Petit, E ; Cartron, PF ; Oliver, L ; Vallette, FM	The phosphorylation of Metaxin 1 controls Bak activation during TNF α induced cell death.	Cell Signal	2017	30	171-178

Lorimier, G ; Linot, B ; Paillocher, N ; Dupoirson, D ; Verri�re, V ; Wernert, R & al	Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer.	Eur J Surg Oncol	2017	43	150-158
Faivre, S ; Niccoli, P ; Castellano, D ; Valle, JW ; Hammel, P ; Raoul, JL & al	Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.	Ann Oncol	2017	28	339-343
De Seta, D ; Torres, R ; Russo, FY ; Ferrary, E ; Kazmitcheff, G ; Heymann, D & al	Damage to inner ear structure during cochlear implantation: Correlation between insertion force and radio-histological findings in temporal bone specimens.	Hear Res	2017	344	90-97
Mart�n, M ; Chan, A ; Dirix, L ; O'Shaughnessy, J ; Hegg, R ; Manikhas, A & al	A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).	Ann Oncol	2017	28	313-320
Bigot, F ; Boudou-Rouquette, P ; Arrondeau, J ; Thomas-Schoemann, A ; Tlemsani, C ; Chapron, J & al	Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.	Invest New Drugs	2017	35	242-246
Jamard, E ; Volard, B ; Dugu�e, AE ; Legros, A ; Leconte, A ; Clarisse, B & al	BRCA1 allele-specific expression in genetic predisposed breast/ovarian cancer.	Fam Cancer	2017	16	167-171
Chiche, A ; Moumen, M ; Romagnoli, M ; Petit, V ; Lasla, H ; J�z�quel, P & al	p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors.	Oncogene	2017	36	2355-2365
Levy, A ; Bardet, E ; Lacas, B ; Pignon, JP ; Adam, J ; Lacroix, L & al	A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer.	Oncotarget	2017	8	15924-15933
Clavert, A ; Peric, Z ; Brissot, E ; Malard, F ; Guillaume, T ; Delaunay, J & al	Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.	Biol Blood Marrow Transplant	2017	23	140-146
Baudouin, M ; Lamoureux, F ; Jacques, C ; Rodriguez Calleja, L ; Quillard, T ; Charrier, C & al	Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis.	Bone	2017	94	10-21
Peyraga, G ; Linot, B ; Yossi, S ; Gustin, P ; Rousseau, D ; Septans, AL & al	Exclusive concurrent radiochemotherapy for advanced head and neck cancers with "fractionated" 5-fluorouracil and cisplatin.	Anticancer Drugs	2017	28	213-221
Delhorme, JB ; Honor�e, C ; Benhaim, L ; Dumont, F ; Dartigues, P ; Dromain, C & al	Long-term survival after aggressive treatment of relapsed serosal or distant pseudomyxoma peritonei.	Eur J Surg Oncol	2017	43	159-167
Bielle, F ; Ducray, F ; Mokhtari, K ; Dehais, C ; Adle-Biassette, H ; Carpentier, C & al	Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomas.	Brain Pathol	2017	27	567-579
Chouaid, C ; Falchero, L ; Schott, R ; Bonnetain, F ;	[Bevacizumab in combination with first-line treatment for metastatic	Rev Mal Respir	2017	34	36-43

Taguieva-Pioger, N ; Bennouna, J	non-small cell lung cancer in clinical practice. Results of the EOLE study].				
Dumont, F ; Thibaudeau, E ; Benhaïm, L ; Gouy, S ; Labbe, D ; Honoré, C & al	Single-port endoscopic mesocolic and mesorectal excision using an extraperitoneal approach.	Surg Endosc	2017	31	469-475
Diab, M ; Nguyen, F ; Berthaud, M ; Maurel, C ; Gaschet, J ; Verger, E & al	Production and characterization of monoclonal antibodies specific for canine CD138 (syndecan-1) for nuclear medicine preclinical trials on spontaneous tumours.	Vet Comp Oncol	2017	15	932-951
Krhili, S ; Muratet, JP ; Roche, S ; Pointreau, Y ; Yossi, S ; Septans, AL & al	Use of Metabolic Parameters as Prognostic Factors During Concomitant Chemoradiotherapy for Locally Advanced Cervical Cancer.	Am J Clin Oncol	2017	40	250-255
Bonnaud-Antignac, A ; Bourdon, M ; Dréno, B ; Quéreux, G	Coping Strategies at the Time of Diagnosis and Quality of Life 2 Years Later: A Study in Primary Cutaneous Melanoma Patients.	Cancer Nurs	2017	40	E45-E53
Denis, F ; Yossi, S ; Septans, AL ; Charron, A ; Voog, E ; Dupuis, O & al	Improving Survival in Patients Treated for a Lung Cancer Using Self-Evaluated Symptoms Reported Through a Web Application.	Am J Clin Oncol	2017	40	464-469